Teva attracts attention from pharma, private equity for $500M sale of Medis: Bloomberg | Fierce Pharma
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth | Ctech
Teva CEO Vigodman Steps Down After Poor Outlook for 2017 | Fortune
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
Adderall hard to find at pharmacies after labor shortage at U.S. supplier
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Pharmaceuticals to Buy Allergan's Generics Business - The New York Times
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Price-fixing lawsuit deals another blow to already fragile Teva, experts say | The Times of Israel
Teva CEO Rejects Netanyahu Plea to Salvage Jerusalem Plant - Bloomberg
Teva to lay off 25% of workforce, suspends dividend - BNN Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - BNN Bloomberg
Teva Abandons Search to Make Covid-19 Vaccine for Partners - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
U.S. charges Teva in generic drugs price-fixing probe
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Intas To Buy Teva's UK, Ireland Assets For 603 Million Pounds
Drugmaker Teva makes $40B bid for rival Mylan
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva considering cutting up to 10,000 jobs: Bloomberg | Reuters
Teva Pharmaceutical: Value at Last - WSJ
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
